Lakewood-Amedex's Nu-3 Shows Strong Activity Against Resistant Diabetic Foot Ulcer Pathogens
Event summary
- Lakewood-Amedex reported positive MIC data for Nu-3 against recent clinical isolates from infected diabetic foot ulcers (iDFU).
- Nu-3 demonstrated consistent activity against resistant pathogens like MRSA and VRE, with MIC values 2-8 times lower than planned clinical doses.
- Phase 2a trial for Nu-3 in mildly infected diabetic foot ulcers is ongoing, with topline data expected in Q1 2027.
The big picture
Lakewood-Amedex's positive data for Nu-3 comes amid growing concerns over antibiotic resistance, particularly in diabetic foot ulcers, which affect millions globally. The company's Bisphosphocin® platform aims to address this unmet need with a novel class of fast-acting antimicrobials. The strategic significance lies in Nu-3's potential to reduce hospitalizations and amputations, a critical outcome for patients with diabetes.
What we're watching
- Clinical Trial Progress
- How the Phase 2a trial results in Q1 2027 will validate Nu-3's efficacy and safety in real-world settings.
- Regulatory Pathway
- Whether the positive MIC data will accelerate regulatory discussions for Nu-3's approval.
- Market Differentiation
- The pace at which Lakewood-Amedex can position Nu-3 as a leading treatment for antibiotic-resistant diabetic foot infections.
Related topics